AAPL   328.60 (+1.95%)
MSFT   185.57 (+1.45%)
FB   230.30 (+1.57%)
GOOGL   1,433.94 (+1.07%)
AMZN   2,467.65 (+0.29%)
CGC   16.97 (+2.04%)
BABA   219.59 (+0.71%)
MU   53.76 (+4.92%)
GE   8.31 (+7.36%)
AMD   52.47 (-0.30%)
ACB   13.92 (-2.18%)
F   7.29 (+10.96%)
DIS   126.91 (+2.60%)
NFLX   414.56 (+0.06%)
BAC   28.41 (+6.05%)
BA   214.89 (+16.60%)
AAPL   328.60 (+1.95%)
MSFT   185.57 (+1.45%)
FB   230.30 (+1.57%)
GOOGL   1,433.94 (+1.07%)
AMZN   2,467.65 (+0.29%)
CGC   16.97 (+2.04%)
BABA   219.59 (+0.71%)
MU   53.76 (+4.92%)
GE   8.31 (+7.36%)
AMD   52.47 (-0.30%)
ACB   13.92 (-2.18%)
F   7.29 (+10.96%)
DIS   126.91 (+2.60%)
NFLX   414.56 (+0.06%)
BAC   28.41 (+6.05%)
BA   214.89 (+16.60%)
AAPL   328.60 (+1.95%)
MSFT   185.57 (+1.45%)
FB   230.30 (+1.57%)
GOOGL   1,433.94 (+1.07%)
AMZN   2,467.65 (+0.29%)
CGC   16.97 (+2.04%)
BABA   219.59 (+0.71%)
MU   53.76 (+4.92%)
GE   8.31 (+7.36%)
AMD   52.47 (-0.30%)
ACB   13.92 (-2.18%)
F   7.29 (+10.96%)
DIS   126.91 (+2.60%)
NFLX   414.56 (+0.06%)
BAC   28.41 (+6.05%)
BA   214.89 (+16.60%)
AAPL   328.60 (+1.95%)
MSFT   185.57 (+1.45%)
FB   230.30 (+1.57%)
GOOGL   1,433.94 (+1.07%)
AMZN   2,467.65 (+0.29%)
CGC   16.97 (+2.04%)
BABA   219.59 (+0.71%)
MU   53.76 (+4.92%)
GE   8.31 (+7.36%)
AMD   52.47 (-0.30%)
ACB   13.92 (-2.18%)
F   7.29 (+10.96%)
DIS   126.91 (+2.60%)
NFLX   414.56 (+0.06%)
BAC   28.41 (+6.05%)
BA   214.89 (+16.60%)
Log in

NYSE:ARPOAerpio Pharmaceuticals Stock Price, Forecast & News

$1.16
0.00 (0.00 %)
(As of 06/5/2020 11:33 AM ET)
Add
Compare
Today's Range
$1.13
Now: $1.16
$1.19
50-Day Range
$0.52
MA: $0.75
$1.13
52-Week Range
$0.42
Now: $1.16
$1.53
Volume271,719 shs
Average Volume1.32 million shs
Market Capitalization$47.08 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio. Aerpio Pharmaceuticals, Inc.(OTCPK:ARPO) operates independently of Akebia Therapeutics, Inc. as of December 22, 2011.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone513-985-1920

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$47.08 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive ARPO News and Ratings via Email

Sign-up to receive the latest news and ratings for ARPO and its competitors with MarketBeat's FREE daily newsletter.

Aerpio Pharmaceuticals (NYSE:ARPO) Frequently Asked Questions

How has Aerpio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Aerpio Pharmaceuticals' stock was trading at $0.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARPO stock has increased by 114.8% and is now trading at $1.16. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aerpio Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerpio Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Aerpio Pharmaceuticals.

When is Aerpio Pharmaceuticals' next earnings date?

Aerpio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Aerpio Pharmaceuticals.

How were Aerpio Pharmaceuticals' earnings last quarter?

Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) issued its earnings results on Thursday, May, 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. View Aerpio Pharmaceuticals' earnings history.

Has Aerpio Pharmaceuticals been receiving favorable news coverage?

News stories about ARPO stock have trended somewhat positive this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aerpio Pharmaceuticals earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutAerpio Pharmaceuticals.

Who are some of Aerpio Pharmaceuticals' key competitors?

What other stocks do shareholders of Aerpio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerpio Pharmaceuticals investors own include SCYNEXIS (SCYX), Innovative Industrial Properties (IIPR), The Ensign Group (ENSG), MYR Group (MYRG), Acasti Pharma (ACST), Aphria (APHA), Avid Technology (AVID), JAKKS Pacific (JAKK), JPMorgan Chase & Co. (JPM) and Neurometrix (NURO).

Who are Aerpio Pharmaceuticals' key executives?

Aerpio Pharmaceuticals' management team includes the following people:
  • Dr. Stephen J. Hoffman, CEO & Director (Age 65)
  • Dr. Joseph H. Gardner, Founder, Pres & Director (Age 63)
  • Mr. Michael W. Rogers, Chief Financial Officer (Age 59)
  • Dr. Stephen Pakola, Chief Medical Officer (Age 50)
  • Mr. Kevin G. Peters, Chief Scientific Officer (Age 62)

What is Aerpio Pharmaceuticals' stock symbol?

Aerpio Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "ARPO."

How do I buy shares of Aerpio Pharmaceuticals?

Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aerpio Pharmaceuticals' stock price today?

One share of ARPO stock can currently be purchased for approximately $1.16.

How big of a company is Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals has a market capitalization of $47.08 million.

What is Aerpio Pharmaceuticals' official website?

The official website for Aerpio Pharmaceuticals is www.aerpio.com.

How can I contact Aerpio Pharmaceuticals?

The company can be reached via phone at 513-985-1920.

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.